BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

742 related articles for article (PubMed ID: 25884197)

  • 1. Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls.
    Kelley RK; Magbanua MJ; Butler TM; Collisson EA; Hwang J; Sidiropoulos N; Evason K; McWhirter RM; Hameed B; Wayne EM; Yao FY; Venook AP; Park JW
    BMC Cancer; 2015 Mar; 15():206. PubMed ID: 25884197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma.
    Schulze K; Gasch C; Staufer K; Nashan B; Lohse AW; Pantel K; Riethdorf S; Wege H
    Int J Cancer; 2013 Nov; 133(9):2165-71. PubMed ID: 23616258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection.
    Sun YF; Xu Y; Yang XR; Guo W; Zhang X; Qiu SJ; Shi RY; Hu B; Zhou J; Fan J
    Hepatology; 2013 Apr; 57(4):1458-68. PubMed ID: 23175471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A New Cell Block Method for Multiple Immunohistochemical Analysis of Circulating Tumor Cells in Patients with Liver Cancer.
    Nam SJ; Yeo HY; Chang HJ; Kim BH; Hong EK; Park JW
    Cancer Res Treat; 2016 Oct; 48(4):1229-1242. PubMed ID: 27034142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of preoperative EpCAM Circulating Tumor Cells and peripheral Treg cell levels with early recurrence of hepatocellular carcinoma following radical hepatic resection.
    Zhou Y; Wang B; Wu J; Zhang C; Zhou Y; Yang X; Zhou J; Guo W; Fan J
    BMC Cancer; 2016 Jul; 16():506. PubMed ID: 27439521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of EpCAM mRNA-positive circulating tumor cells in hepatocellular carcinoma by an optimized negative enrichment and qRT-PCR-based platform.
    Guo W; Yang XR; Sun YF; Shen MN; Ma XL; Wu J; Zhang CY; Zhou Y; Xu Y; Hu B; Zhang X; Zhou J; Fan J
    Clin Cancer Res; 2014 Sep; 20(18):4794-805. PubMed ID: 25009297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Tumor Cells Undergoing EMT Provide a Metric for Diagnosis and Prognosis of Patients with Hepatocellular Carcinoma.
    Qi LN; Xiang BD; Wu FX; Ye JZ; Zhong JH; Wang YY; Chen YY; Chen ZS; Ma L; Chen J; Gong WF; Han ZG; Lu Y; Shang JJ; Li LQ
    Cancer Res; 2018 Aug; 78(16):4731-4744. PubMed ID: 29915159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IGFBP1 in epithelial circulating tumor cells as a potential response marker to selective internal radiation therapy in hepatocellular carcinoma.
    Nel I; Baba HA; Weber F; Sitek B; Eisenacher M; Meyer HE; Schlaak JF; Hoffmann AC
    Biomark Med; 2014; 8(5):687-98. PubMed ID: 25123037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An improved strategy to detect the epithelial-mesenchymal transition process in circulating tumor cells in hepatocellular carcinoma patients.
    Liu YK; Hu BS; Li ZL; He X; Li Y; Lu LG
    Hepatol Int; 2016 Jul; 10(4):640-6. PubMed ID: 27115761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma.
    Court CM; Hou S; Winograd P; Segel NH; Li QW; Zhu Y; Sadeghi S; Finn RS; Ganapathy E; Song M; French SW; Naini BV; Sho S; Kaldas FM; Busuttil RW; Tomlinson JS; Tseng HR; Agopian VG
    Liver Transpl; 2018 Jul; 24(7):946-960. PubMed ID: 29624843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients.
    Königsberg R; Obermayr E; Bises G; Pfeiler G; Gneist M; Wrba F; de Santis M; Zeillinger R; Hudec M; Dittrich C
    Acta Oncol; 2011 Jun; 50(5):700-10. PubMed ID: 21261508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantified postsurgical small cell size CTCs and EpCAM
    Wang L; Li Y; Xu J; Zhang A; Wang X; Tang R; Zhang X; Yin H; Liu M; Wang DD; Lin PP; Shen L; Dong J
    Cancer Lett; 2018 Jan; 412():99-107. PubMed ID: 29031565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Detection of circulating tumor cells in patients with hepatocellular carcinoma].
    Mu H; Lin K; Zhao H; Li C; Sun Y; Cai J; Zhao X
    Zhonghua Zhong Liu Za Zhi; 2014 Apr; 36(4):276-81. PubMed ID: 24989914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumor cells detected with a microcavity array predict clinical outcome in hepatocellular carcinoma.
    Takahashi K; Ofuji K; Hiramatsu K; Nosaka T; Naito T; Matsuda H; Endo K; Higuchi M; Ohtani M; Nemoto T; Nakamoto Y
    Cancer Med; 2021 Apr; 10(7):2300-2309. PubMed ID: 33675149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AFP mRNA level in enriched circulating tumor cells from hepatocellular carcinoma patient blood samples is a pivotal predictive marker for metastasis.
    Jin J; Niu X; Zou L; Li L; Li S; Han J; Zhang P; Song J; Xiao F
    Cancer Lett; 2016 Aug; 378(1):33-7. PubMed ID: 27160647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer.
    Schneck H; Gierke B; Uppenkamp F; Behrens B; Niederacher D; Stoecklein NH; Templin MF; Pawlak M; Fehm T; Neubauer H;
    PLoS One; 2015; 10(12):e0144535. PubMed ID: 26695635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor cell enumeration with a combination of epithelial cell adhesion molecule- and cell-surface vimentin-based methods for monitoring breast cancer therapeutic response.
    Satelli A; Brownlee Z; Mitra A; Meng QH; Li S
    Clin Chem; 2015 Jan; 61(1):259-66. PubMed ID: 25336717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical significance of CTC enrichment by GPC3-IML and its genetic analysis in hepatocellular carcinoma.
    Yi B; Wu T; Zhu N; Huang Y; Yang X; Yuan L; Wu Y; Liang X; Jiang X
    J Nanobiotechnology; 2021 Mar; 19(1):74. PubMed ID: 33726759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mesenchymal circulating tumor cells as biomarker for prognosis prediction and supervision in hepatocellular carcinoma.
    Zhao L; Zheng Z; Liu Y; Liu F; Li X; Wu Z
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6035-6048. PubMed ID: 36633681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.